8-K: Stryker Q1 2026 Earnings: Sales Growth Amid Cyber Recovery

Stryker reported a 2.6% increase in Q1 2026 net sales to $6.0 billion, maintaining full-year guidance despite a recent cybersecurity incident.

Summary

• Reported net sales reached $6.0 billion, a 2.6% increase year-over-year.
• Organic net sales grew by 2.4%, driven by a 2.1% increase in unit volume and 0.3% from pricing.
• Reported EPS rose 14.2% to $1.93, while adjusted EPS fell 8.5% to $2.60.
• Reported operating income margin was 15.5%, with an adjusted operating income margin of 21.1%.
• The company implemented a new organizational structure, creating an 'Ortho Tech' business unit to streamline operations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a stable performance; while earnings metrics declined, the reaffirmation of full-year guidance and successful navigation of a cyber incident provide a neutral-to-positive outlook.

Positives

• Reported net sales increased 2.6% to $6.0 billion.
• Reported EPS grew 14.2% to $1.93.
• Organic net sales growth of 2.4% demonstrates underlying business resilience.
• Management reaffirmed full-year 2026 guidance for organic sales growth and adjusted EPS.
• Successful recovery from the cybersecurity incident reported on March 11, 2026.

Negatives

• Adjusted EPS decreased 8.5% to $2.60.
• Adjusted operating income margin contracted 180 basis points to 21.1%.
• Adjusted net earnings fell 8.5% to $1.0 billion.
• Orthopaedics segment saw a 1.8% decrease in constant currency net sales.
• Reported gross profit margin declined from 63.8% to 63.3%.

Risks

• Ongoing impact of the cybersecurity incident first reported on March 11, 2026.
• Geopolitical risks, including tariffs and international conflicts affecting supply chains.
• Pricing pressures and healthcare cost-containment measures.
• Potential for product liability claims and recall-related costs.
• Regulatory and legal matters, including compliance with medical device regulations.

Future Outlook

Stryker maintains its full-year 2026 guidance, targeting organic net sales growth of 8.0% to 9.5% and adjusted net earnings per diluted share of $14.90 to $15.10.

Management Comments

• I am pleased with our teams ability to recover quickly from the cyber incident and continue delivering for our customers and their patients.
• We remain committed to meeting our full year guidance for organic sales growth and adjusted earnings per share as our underlying business momentum remains strong.

Industry Context

StockSavvy.ai notes that Stryker's ability to maintain guidance despite a significant cybersecurity event highlights the defensive nature of the medical device sector and the company's operational scale compared to smaller peers.

Comparison to Industry Standards

• Stryker's organic growth of 2.4% remains competitive within the large-cap MedTech space.
• The 21.1% adjusted operating margin is consistent with top-tier medical device manufacturers like Medtronic and Zimmer Biomet.
• The restructuring into 'Ortho Tech' aligns with industry trends toward integrated digital and robotic surgical ecosystems.

Corporate Governance

Legal Proceedings

• The company is managing various regulatory and legal matters, including recall-related costs and compliance with medical device regulations.

Stakeholder Impact

• Shareholders: Reaffirmed guidance suggests stability in dividend and earnings potential.
• Customers: New organizational structure aims to improve service delivery and innovation speed.
• Employees: Restructuring may involve internal team realignments.

Next Steps

• Host conference call on April 30, 2026.
• Continue integration of the new Ortho Tech business unit.
• Monitor ongoing impacts of the March 2026 cybersecurity incident.

Key Dates

Recommendation

The stock is a hold as the company navigates the aftermath of a cyber incident and organizational restructuring, with current valuation likely priced in against the reaffirmed full-year guidance.

Keywords

Stryker, Medical Technology, Q1 2026 Earnings, MedSurg, Orthopaedics, Cybersecurity Incident, Organic Growth